Dermatomyositis — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Glutamine antagonist DON attenuates chikungunya virus-induced myositis by suppressing inflammatory activation in a murine model.
Zhang Xinyu et al. — Emerging microbes & infections (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41790543/
- 2.
The role of extracorporeal membrane oxygenation in the management of rapidly progressive interstitial lung disease due to anti-melanoma differentiation-associated gene 5 antibody dermatomyositis: A case series and brief literature review.
Jurica James M et al. — JHLT open (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41852368/
- 3.
A Case of Pleomorphic Carcinoma of the Lung Complicated by Anti-HMGCR Antibody-Positive Necrotizing Myositis.
Sadahiro Kozaburo et al. — The Tokai journal of experimental and clinical medicine (20 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41859803/
- 4.
Compassionate use efficacy of the interferon-beta inhibitor dazukibart in dermatomyositis.
Vleugels Ruth Ann et al. — Journal of the European Academy of Dermatology and Venereology : JEADV (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41879078/
- 5.
Checkerboard Hyperkeratosis With Apoptotic Keratinocytes as Features of Mechanic's Hands and Review of the Literature.
Long Valencia et al. — The American Journal of dermatopathology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41849753/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of AZD0120 in Autoimmune Diseases
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07295847
- 2.
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
Recruiting — Na — McMaster University
https://clinicaltrials.gov/study/NCT03127631
- 3.
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Recruiting — Phase 1 — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
https://clinicaltrials.gov/study/NCT07115745
- 4.
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Recruiting — Phase 1 — Chugai Pharmaceutical
https://clinicaltrials.gov/study/NCT06371417
- 5.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT03486873
- 6.
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Recruiting — Phase 3 — AstraZeneca
https://clinicaltrials.gov/study/NCT06455449
- 7.
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
Recruiting — Phase 3 — Population Health Research Institute
https://clinicaltrials.gov/study/NCT04774159
- 8.
To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
Recruiting — Phase 2 — Incyte Corporation
https://clinicaltrials.gov/study/NCT05090891
- 9.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Dermatomyositis
Dermatomyositis is a rare autoimmune condition causing muscle inflammation and weakness, accompanied by characteristic skin rashes. It is part of the inflammatory myopathy group. It can be associated with internal cancers in adults. Immunosuppressive therapy is the main treatment, with newer biologic agents showing promise.
Most Recent Research
Chikungunya virus (CHIKV), an emerging mosquito-borne alphavirus, induces debilitating polyarthralgia and myositis with no licensed specific therapeutic drugs. This study investigates the virological, immunological, and pathological consequences of targeting glycolysis and glutaminolysis during CHIKV infection. In vitro, either glucose/glutamine deprivation, or pharmacological inhibition by 2DG/DON significantly suppressed viral replication in mammalian cell lines. In vivo, however, differential tissue biodistribution dictated that neither inhibitor reduced viral loads in serum or foot tissues of acute infected mice following footpad inoculation with 10⁴ PFU CHIKV. Strikingly, DON, but not 2DG, abolished histopathological manifestations of myositis and inflammatory infiltration despite comparable viral burdens. Mechanistically, DON-mediated tissue protection was related to dual immunomodulation. DON significantly depleted splenic innate immune cells, including monocytes and macrophages, which play roles in driving tissue inflammatory infiltration cascades. Meanwhile, DON inhibited CD4 + and CD8+ T cell effector programmes, resulting in suppressed activation marker (CD44) expression and effector cell differentiation (decreased effector: naive ratio and TEM: TCM balance). The proliferative capacity (Ki-67 + cells), polyfunctional cytokine responses (IFN-γ+, TNF-α and IL-17 + cells) and cytotoxicity potential (CD107a + cells) of CD4 + and CD8+ T cells were significantly impaired by DON injection. Crucially, glutaminolysis inhibition uncoupled immunopathology from viral containment, attenuating tissue damaging immunity while preserving baseline antiviral competence. Collectively, these findings establish host glutamine metabolism as a pharmacologically tractable target for alphavirus-induced arthritis, demonstrating that selective immunometabolic modulation resolves the severe acute inflammatory pathology.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.